MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Apellis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

19.46 -3.09

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.19

Max

19.73

Galvenie mērījumi

By Trading Economics

Ienākumi

-56M

-92M

Pārdošana

-46M

167M

Peļņas marža

-55.292

Darbinieki

705

EBITDA

-56M

-80M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+85.88% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 31. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-54M

2.5B

Iepriekšējā atvēršanas cena

22.55

Iepriekšējā slēgšanas cena

19.46

Ziņu noskaņojums

By Acuity

71%

29%

339 / 376 Rangs Healthcare

Apellis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 18. jūl. 21:01 UTC

Peļņas

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

2025. g. 18. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 18. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 18. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 18. jūl. 20:46 UTC

Peļņas

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

2025. g. 18. jūl. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025. g. 18. jūl. 20:36 UTC

Peļņas

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

2025. g. 18. jūl. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

2025. g. 18. jūl. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 18. jūl. 20:02 UTC

Tirgus saruna

Gold Higher to Close Out Week -- Market Talk

2025. g. 18. jūl. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

2025. g. 18. jūl. 19:06 UTC

Tirgus saruna

Oil Futures Snap Two-Week Winning Streak -- Market Talk

2025. g. 18. jūl. 18:24 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

2025. g. 18. jūl. 18:19 UTC

Peļņas

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

2025. g. 18. jūl. 18:11 UTC

Iegādes, apvienošanās, pārņemšana

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

2025. g. 18. jūl. 18:11 UTC

Peļņas

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

2025. g. 18. jūl. 17:35 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

2025. g. 18. jūl. 16:29 UTC

Tirgus saruna

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

2025. g. 18. jūl. 16:28 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025. g. 18. jūl. 16:22 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Energy & Utilities Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 18. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 18. jūl. 16:04 UTC

Peļņas

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

2025. g. 18. jūl. 15:58 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 18. jūl. 15:58 UTC

Tirgus saruna

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

2025. g. 18. jūl. 15:47 UTC

Tirgus saruna
Peļņas

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Salīdzinājums

Cenas izmaiņa

Apellis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

85.88% augšup

Prognoze 12 mēnešiem

Vidējais 37.25 USD  85.88%

Augstākais 60 USD

Zemākais 17 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Apellis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

10

Pirkt

7

Turēt

0

Pārdot

Noskaņojums

By Acuity

339 / 376 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.